Treatment response based on the emergence phase of ACAs
| Phase . | Group 1 . | Group 2 . | ||||
|---|---|---|---|---|---|---|
| Trisomy 8 . | −Y . | Extra Ph . | i(17)(q10) . | −7/del(7q) . | 3q26 . | |
| CP | ||||||
| CCyR | 12/21 (57%) | 17/26 (65%) | 11/16 (69%) | 2/9 (22%) | 1/3 (33%) | 0/11 (0%) |
| MMR | 11/21 (52%) | 16/26 (62%) | 9/16 (56%) | 1/9 (11%) | 0/3 (0%) | 0/11 (0%) |
| AP + BP | ||||||
| CCyR | 0/1 (0%) | N/A | 1/3 (33%) | 0/6 (0%) | 0/1 (0%) | 0/8 (0%) |
| MMR | 0/1 (0%) | N/A | 1/3 (33%) | 0/6 (0%) | 0/1 (0%) | 0/8 (0%) |
| Phase . | Group 1 . | Group 2 . | ||||
|---|---|---|---|---|---|---|
| Trisomy 8 . | −Y . | Extra Ph . | i(17)(q10) . | −7/del(7q) . | 3q26 . | |
| CP | ||||||
| CCyR | 12/21 (57%) | 17/26 (65%) | 11/16 (69%) | 2/9 (22%) | 1/3 (33%) | 0/11 (0%) |
| MMR | 11/21 (52%) | 16/26 (62%) | 9/16 (56%) | 1/9 (11%) | 0/3 (0%) | 0/11 (0%) |
| AP + BP | ||||||
| CCyR | 0/1 (0%) | N/A | 1/3 (33%) | 0/6 (0%) | 0/1 (0%) | 0/8 (0%) |
| MMR | 0/1 (0%) | N/A | 1/3 (33%) | 0/6 (0%) | 0/1 (0%) | 0/8 (0%) |
N/A, not available.